Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
21 hedge funds and large institutions have $4.98M invested in Oncternal Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 7 closing their positions.
0.87% more ownership
Funds ownership: 7.33% → 8.19% (+0.87%)
12% less capital invested
Capital invested by funds: $5.64M → $4.98M (-$654K)
16% less funds holding
Funds holding: 25 → 21 (-4)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$852K |
| 2 |
Renaissance Technologies
New York
|
+$109K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$70.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.8K |
| 5 |
Morgan Stanley
New York
|
+$14.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$156K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$66K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$64.3K |
| 4 |
DY
Dowling & Yahnke
San Diego,
California
|
-$35.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$18.4K |
ONCT Hedge Fund Activity: Q4 2019 in Review
21 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2019, worth a combined $4.98M — down 12% from $5.64M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ONCT and 3 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $852K. The largest seller was Millennium Management, cutting an estimated $156K.
- 21 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2019, down from 25 in Q3 2019.
- Funds reported $4.98M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2019, down 12% quarter-over-quarter.
- 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2019 and 7 closed out, a net change of -4 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2019 was Vanguard Group, an estimated $852K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2019 was Millennium Management, an estimated $156K sold.
Based on aggregated 13F filings for Q4 2019.